Download as PDF
PreveCeutical™ Medical Inc. Begins Trading on the Frankfurt Stock Exchange
August 1, 2017, Vancouver, British Columbia: PreveCeutical™ Medical Inc. (the “Company” or “PreveCeutical”) (CSE: PREV) announces the listing of its common shares for trading on the Frankfurt Stock Exchange (“FSE”) under the symbol "18H". The Company's common shares now trade concurrently on the FSE and on the Canadian Securities Exchange (CSE) under the symbol "PREV".
The Frankfurt Stock Exchange is one of the world’s largest, behind only the Nasdaq and NYSE, organized exchange-trading markets in terms of turnover and dealings in securities. The electronic trading platform of the FSE, XETRA, has made it the world’s second-largest fully electronic cash market with direct linkage to all other major European financial hubs. Listing on the FSE will help increase PreveCeutical’s trading liquidity and facilitate investment in the Company by European investors across the Frankfurt listings major financial hubs like Switzerland, Luxembourg, Lichtenstein, Monaco among others.
PreveCeutical’s Chairman and CEO, Mr. Stephen Van Deventer commented, “We are pleased to have the Company listed on the Frankfurt Stock Exchange. Obtaining this listing will give PreveCeutical exposure to a much larger potential investor base and provide increased access to the European capital markets.”
About PreveCeutical Medical Inc.
PreveCeutical Medical Inc. (CSE: PREV) is a biomedical company that coined the platform for preventive health sciences. PreveCeutical’s innovative research and development department advances organic and Nature Identical products for both prevention and curative therapies.
The Company currently has one product available for sale, the CELLB9® Immune System Booster. CELLB9® is an oral solution containing polarized and potentiated essential minerals extracted from a novel peptide obtained from Caribbean Blue Scorpion venom. The active potentiated ingredients in the Blue Scorpion venom appear to support health at a deep cellular level, having been used for many years and in over 40 countries. The solution is colourless and odourless and can be administered orally.
For more information about PreveCeutical, please visit www.PreveCeutical.com, follow us on Twitter: http://twitter.com/PreveCeuticals and Facebook: www.facebook.com/PreveCeutical.
On Behalf of the Board of Directors
Stephen Van Deventer
Chairman & CEO
For further information, please contact:
Deanna Kress
Director of Corporate Communications & Investor Relations
+1-778-999-6063
deanna@preveceutical.com
Forward-Looking Statements:
This news release includes certain statements that constitute “forward-looking information” within the meaning of applicable Canadian securities laws. Readers are cautioned that forward-looking statements are not guarantees of future performance or events and, accordingly, are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty of such statements. Statements in this news release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations and orientations regarding the future. Often, but not always, forward-looking statements can be identified by words such as “pro forma”, “plans”, “expects”, “may”, “should”, “budget”, “schedules”, “estimates”, “forecasts”, “intends”, “anticipates”, “believes”, “potential” or variations of such words including negative variations thereof and phrases that refer to certain actions, events or results that may, could, would, might or will occur or be taken or achieved. Such forward-looking statements include, among others, statements as to the proposed first phase of the Company's venom re-engineering project, business plans of the Company regarding the foregoing, the timing of future activities and the prospects of their success for the Company, and the Company’s ability and success in executing its proposed business plans, including a successful IND application. Actual results could differ from those projected in any forward-looking statements due to numerous factors including risks and uncertainties relating to the inability of the Company, to, among other things, complete the proposed research project as planned or the inability of the Company to obtain any required governmental approvals, permits, consents or authorizations required, including Canadian Securities Exchange acceptance of any planned future activities, or financing required to carry out its planned future activities. Other factors such as general economic, market or business conditions or changes in laws, regulations and policies affecting the biotechnology or pharmaceutical industry, may also adversely affect the future results or performance of the Company, including the completion of the proposed research programs. There is no guarantee that the research programs will be successful or that their results can be commercialised by the Company. These forward-looking statements are made as of the date of this news release and, unless required by applicable law, the Company assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in these forward-looking statements. Although the Company believes that the statements, beliefs, plans, expectations, and intentions contained in this news release are reasonable, there can be no assurance that those statements, beliefs, plans, expectations, or intentions will prove to be accurate. Readers should consider all of the information set forth herein and should also refer to other periodic reports provided by the Company from time-to-time. These reports and the Company’s filings are available at www.sedar.com.